Previous 10 | Next 10 |
CytoSorbents Corporation (CTSO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Michelle Almonte - Executive Assistant to CEO Phillip Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Christian Steiner -...
Cytosorbents press release ( NASDAQ: CTSO ): Q3 GAAP EPS of -$0.28 misses by $0.12 . Revenue of $8.1M (-17.0% Y/Y) misses by $0.42M . We expect that our business, and in particular product sales, will continue to be challenging for the remainder of 2022 and int...
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results PR Newswire CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month PRINCETON, N.J. , Nov. 3, 2022 /PRNewswire/ -- CytoSorbents C...
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals PR Newswire 90-day survival was 74% overall, with early intervention with ECMO and CytoSorb associat...
National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma PR Newswire Goal is to advance new combined blood purification technologies to treat Gram negative sepsis ȁ...
CytoSorbents to Report Third Quarter 2022 Operating and Financial Results PR Newswire PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care u...
CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting PR Newswire PRINCETON, N.J. , Oct. 12, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leade...
CytoSorbents ( NASDAQ: CTSO ) CFO Kathleen Bloch plans to retire on Mar. 31, 2023. The company is looking for a replacement for Bloch. Bloch will continue as a consultant of the company. Source: Press Release For further details see: Cy...
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch PR Newswire PRINCETON, N.J. , Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the inte...
CytoSorbents ( NASDAQ: CTSO ) notifies that the U.S. Army Medical Research Acquisition Activity has awarded the company a three-year Phase III contract valued at $4,292,641 to enable freeze-dried universal plasma using its HemoDefend-BGA technology. Without the n...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...